Page 81 - ITPS-8-2

INNOSC Theranostics and
Pharmacological Sciences Ketamine and SOD activity in schizophrenia

antipsychotics. Neurosci Lett. 2010;479(3):317-320. on dopaminergic function: Meta-analysis and review of the
implications for neuropsychiatric disorders. Mol Psychiatry.
doi: 10.1016/j.neulet.2010.05.088
2018;23(1):59-69.
5. Parise EM, Alcantara LF, Warren BL, et al. Repeated ketamine
exposure induces an enduring resilient phenotype in adolescent doi: 10.1038/mp.2017.190
and adult rats. Biol Psychiatry. 2013;74(10):750-759. 15. Frohlich J, Van Horn JD. Reviewing the ketamine model for
schizophrenia. J Psychopharmacol. 2014;28(4):287-302.
doi: 10.1016/j.biopsych.2013.04.027
doi: 10.1177/0269881113512909
6. Usman Y, Aderibigbe AO, Benneth, BA, Fehintola FA.
Antipsychotic effects of ethanol extract of Blighia sapida 16. Malik JA, Yaseen Z, Thotapalli L, Ahmed S, Shaikh MF,
(Sapindaecea) stem bark in pharmacological models of Anwar S. Understanding translational research in
psychosis in Swiss mice. Afr J Med Med Sci. 2019;48:151-160. schizophrenia: A novel insight into animal models. Mol Biol
Rep. 2023;50(4):3767-3785.
7. Uliana DL, Zhu X, Gomes FV, Grace AA. Using animal
models for the studies of schizophrenia and depression: The doi: 10.1007/s11033-023-08241-7
value of translational models for treatment and prevention. 17. Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss
Front Behav Neurosci. 2022;16:935320. of phenotype of fast-spiking interneurons is mediated by
doi: 10.3389/fnbeh.2022.935320 NADPH-oxidase. Science. 2007;318(5856):1645-1647.
8. Krystal JH, D’Souza DC, Mathalon D, Perry E, Belger A, doi: 10.1126/science.1148045
Hoffman R. NMDA receptor antagonist effects, 18. Koju N, Qin Z, Sheng R. Reduced nicotinamide adenine
cortical glutamatergic function, and schizophrenia: dinucleotide phosphate in redox balance and diseases:
toward a paradigm shift in medication development. A friend or foe? Acta Pharmacol Sin. 2022;43:1889-1904.
Psychopharmacology (Berl). 2003;169(3-4):215-233.
doi: 10.1038/s41401-021-00838-7
doi: 10.1007/s00213-003-1582-z
19. Wang Y, Branicky R, Noë A, Hekimi S. Superoxide dismutases:
9. Driesen NR, McCarthy G, Bhagwagar Z, et al. The Dual roles in controlling ROS damage and regulating ROS
impact of NMDA receptor blockade on human working signaling. J Cell Biol. 2018;217(6):1915-1928.
memory-related prefrontal function and connectivity.
Neuropsychopharmacology. 2013;38(13):2613-2622. doi: 10.1083/jcb.201708007
doi: 10.1038/npp.2013.170 20. Stojković T, Radonjić NV, Velimirović M, et al. Risperidone
reverses phencyclidine induced decrease in glutathione
10. Muthukumaraswamy SD, Shaw AD, Jackson LE, Hall J, levels and alterations of antioxidant defense in rat brain. Prog
Moran R, Saxena N. Evidence that sub-anesthetic doses of Neuropsychopharmacol Biol Psychiatry. 2012;39:192-199.
ketamine cause sustained disruptions of NMDA and AMPA-
Mediated frontoparietal connectivity in humans. J Neurosci. doi: 10.1016/j.pnpbp.2012.06.013
2015;35(33):11694-11706. 21. Lang X, Wang DM, Du XD, et al. Elevated activity of
doi: 10.1523/JNEUROSCI.0903-15.2015 plasma superoxide dismutase in never-treated first-
episode schizophrenia patients: Associated with depressive
11. Lindefors N, Barati S, O’Connor WT. Differential effects of symptoms. Schizophrenia Res. 2020;222:291-296.
single and repeated ketamine administration on dopamine,
serotonin and GABA transmission in rat medial prefrontal doi: 10.1016/j.schres.2020.05.032
cortex. Brain Res. 1997;759(2):205-212. 22. Ben-Azu B, Aderibigbe AO, Ajayi AM, Iwalewa EO.
Neuroprotective effects of the ethanol stem bark extracts of
doi: 10.1016/S0006-8993(97)00255-2
Terminalia ivorensis in ketamine-induced schizophrenia-
12. Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, like behaviors and oxidative damage in mice. Pharm Biol.
Neill JC. NMDA receptor antagonist rodent models for 2016;54(12):2871-2879.
cognition in schizophrenia and identification of novel drug
treatments, an update. Neuropharmacology. 2018;142:41-62. doi: 10.1080/13880209.2016.1190382
23. Yan BC, Park JH, Ahn JH, et al. Neuroprotection of post-
doi: 10.1016/j.neuropharm.2017.11.045
treatment with risperidone, an atypical antipsychotic
13. Jürgenson M, Aonurm-Helm A, Zharkovsky A. Behavioral drug, in rat and gerbil models of ischemic stroke and the
profile of mice with impaired cognition in the elevated plus- maintenance of antioxidants in a gerbil model of ischemic
maze due to a deficiency in neural cell adhesion molecule. stroke. J Neurosci Res. 2014;92:795-807.
Pharmacol Biochem Behav. 2010;96(4):461-468.
doi: 10.1002/jnr.23360
doi: 10.1016/j.pbb.2010.07.006
24. Puech C, Badran M, Runion AR, et al. Explicit memory,
14. Kokkinou M, Ashok AH, Howes OD. The effects of ketamine anxiety and depressive like behavior in mice exposed to

Volume 8 Issue 2 (2025) 75 doi: 10.36922/itps.6372